Antikor awarded an Innovate-UK Early Stage award December 2016

December 2016: Antikor has been awarded an Innovate-UK Early Stage award, worth £810,000 to develop a product for Gastric cancer, an indication where Antikor's Fragment-based Antibody Drug Conjugate (FDC) technology can really make an impact.  The Company is now seeking around £600,000 of investment to match-fund the grant.  

Why invest in Antikor?  Antikor has a unique, differentiated delivery platform for small-format Antibody-Drug Conjugates (ADCs), denoted FDCs, that can destroy solid tumours in a way that larger ADCs cannot.  Importantly, Antikor has strong IP to protect products (to 2034). 

Within 2 years, Antikor will have a lead product, extensively protected and which will have significant value.